See ratings and reviews when you sign up for an account.

Evaluation of Intercarpal Botox Versus Steroid Injections for Carpal Tunnel Syndrome

This study is currently Recruiting

November 2010 By University of Minnesota - Clinical and Translational Science Institute

First Recieved on June 17, 2008

Last Updated on November 1, 2010

Sponsor: University of Minnesota - Clinical and Translational Science Institute
Information provided by: University of Minnesota - Clinical and Translational Science Institute
Identifier: NCT00701233


To compare local steroid injections to local Botulinum toxin A injection in a double-blinded study.

Study Type: Interventional
Study Design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Ages Eligible for Study:18 Years
Genders Eligible for Study:Both
Accepts Healthy Volunteers:No

Inclusion Criteria: - Any individual with symptoms of carpal tunnel syndrome and a diagnosis of CTS either clinically or via EMG will be included into this study. There will be a total of 20 subjects displaying symptoms of CTS. The gender of the subjects will not determine enrollment. There is no requirement of male to female ratio for this study. There is no age cut-off or minimal age requirement to enroll in the study. No specific Racial or ethnic restrictions will be present for this study. Female subjects of childbearing potential (not surgically sterile or postmenopausal for at least 2 years) must have a negative pregnancy test at screening. Exclusion Criteria: 1. Any individual who has a diagnosis of CTS (by EMG or other means) but no symptoms of CTS will be excluded from this study. 2. Vulnerable subjects as defined as children, pregnant women, those with limited autonomy, decisional incapacity and prisoners will not be enrolled in this study. 3. Individuals with any history of carpal tunnel release surgery and recurrent or persistent symptoms will be excluded form this study. 4. Subject is pregnant or lactating.


  • Investigator: Dennis Dykstra, MD - Principal Investigator - University of Minnesota - Clinical and Translational Science Institute


  • University of Minnesota PM&R Department

    Minneapolis, Minnesota 55455 United States

Conditions related to this trial:

Disclaimer: The list and ratings above are for informational purposes only, and is intended to supplement, not substitute for, the expertise and judgment of your physician, pharmacist or other healthcare professional. The goal of the information is to provide you with a comprehensive view of all available treatments, but should not be construed to indicate that use of any one treatment is safe, appropriate, or effective for you. Decisions about use of a new treatment, or about a change in your current treatment plan, should be in consultation with your doctor or other healthcare professional.